MS arising during Tocilizumab therapy for rheumatoid arthritis
Conclusion:
This case illustrates that Tocilizumab might cause secondary auto-immunity in CNS. It is important to be aware of this potential complication as anti-IL6 therapy might become an option for the treatment NMOSD.
Source: Multiple Sclerosis - Category: Neurology Authors: Beauchemin, P., Carruthers, R. Tags: Case Report and Clinical Commentary Source Type: research
More News: Actemra | Arthritis | Multiple Sclerosis | Neurology | Rheumatoid Arthritis | Rheumatology